相关实验视频

Updated: Sep 14, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

对Gal-1和基因毒剂的治疗前景

Eric J Sohn¹, Jaewon Min^1,2

¹Institute for Cancer Genetics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

The FEBS journal

|July 24, 2025

概括

加勒-1 (Gal1) 与肺癌中PARP1相互作用,增强DNA修复和减少细胞死亡. Gal1 抑制剂使瘤对化疗重新敏感,提供了新的治疗策略.

科学领域:

分子生物学分子生物学
癌症研究癌症研究
生物化学生物化学

背景情况:

加勒-1 (Gal1) 是一种可溶性莱克,具有多种细胞内和细胞外的作用.
升高的Gal1与癌症信号传递,免疫反应和化疗耐药性有关.
根据癌症类型,Gal1在增殖和细胞死亡中的作用有所不同.

研究的目的:

为了研究在非小细胞肺癌中Galectin-1和PARP1之间的相互作用.
确定这种相互作用对DNA损伤反应和细胞死亡的影响.
为了评估Gal1抑制剂在使瘤重新敏感化疗中的疗效.

主要方法:

使用了非小细胞肺癌细胞系.
研究了Gal1和PARP1.1之间的相互作用.
评估了DNA损伤反应途径.
检查了瘤对带有或没有Gal1抑制剂的埃托波治疗的反应.
研究了PARP1在同源重组和Gal1在细胞转移中的作用.

主要成果:

在非小细胞肺癌细胞中发现了Gal1和PARP1之间的新型相互作用.
这种相互作用增强了DNA损伤反应,导致癌细胞死亡率降低.
Gal1 抑制剂成功地使瘤对埃托化疗重新敏感.
这项研究探讨了PARP1在同源重组中的作用和Gal1在转移中的作用.

结论:

Gal1-PARP1相互作用是非小细胞肺癌对DNA损伤反应的关键因素.
用抑制剂向Gal1代表了克服化疗耐药性的有希望的策略.
对Gal1和PARP1功能的进一步研究可能会揭示肺癌的新治疗点.

关键词:

这是一个ATMATMATM.盖尔1 盖尔1 盖尔1 人力资源部的人力资源部在MRE11中,MRE11是MRE11中的一个.人类 MRN 的人类 MRN 尼希耶 (NHEJ) 是一个 PARP1 的第一部分.

更多相关视频

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry

Published on: September 1, 2019

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

相关概念视频

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...